Program Description
Graft-versus-host
disease (GVHD) remains the primary driver of non-relapse morbidity and
mortality following allogeneic hematopoietic cell transplantation (allo-HCT),
creating a persistent clinical burden and reducing long-term survivorship for
patients. While conventional prophylaxis has improved outcomes, patients still
face significant risks of chronic GVHD, prolonged immunosuppression, and
opportunistic infections. Presented in collaboration with the American Society
for Transplantation and Cellular Therapy, this program will review novel
graft-engineering strategies with faculty offering expert analysis on how these
precision platforms differ from unmanipulated peripheral blood stem cell or
bone marrow grafts. A review of clinical data comparing these
"prophylaxis-light" engineered models against current standards of
care will focus on key survival end points, the reduction of chronic GVHD
burden, and the potential for accelerated, robust immune reconstitution.
Included case-based discussions will examine approaches for oncology and
transplant pharmacists to lead multidisciplinary discussions on graft
selection, anticipate unique safety profiles, and optimize immune recovery for
better quality of life among patients with GVHD.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 29, 2026
Expiration date: April 29, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify graft-engineering strategies for graft-versus-host disease (GVHD) prophylaxis, focusing on mechanisms, efficacy, safety, and clinical impact on chronic GVHD
- Examine evidence on chronic GVHD risk, immune recovery, quality of life, and long-term immunosuppression to guide multidisciplinary care and survivorship in allogeneic transplant recipients
- Adapt operational and logistical factors for integrating emerging prophylaxis platforms, including those exploring reduced or limited GVHD prophylaxis into practical transplant workflows
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here